CD19 expression is increased in peripheral B cells from patients with SSc compared to healthy controls and correlates with disease activity, skin fibrosis, and autoantibody levels (44). Genetic variants of CD19 have been associated with augmented CD19 expression levels, increased susceptibility, and different clinical phenotypes in SSc (47, 48). The gene discussed is CD19; the disease is systemic sclerosis.